6 minute read
Sep. 5, 2023
A Novel Class of Brain-Penetrant, Covalent Antiparasitic Drugs from Novartis
CT3
irreversible trypanosomal topo. II inhibitor efficacy in Chagas and sleeping sickness models from phenotypic screen against trypanosomes Science, June 29, 2023 Novartis (NITD), Emeryville, CA / Singapore
Loading...
